Context Therapeutics Inc. announced on January 13, 2025, the appointment of Andy Pasternak as Chairman of its Board of Directors. Mr. Pasternak succeeds Richard Berman, who stepped down from the Board effective January 12, 2025.
Mr. Pasternak brings over 25 years of experience in the biopharmaceutical sector, including his recent role as Executive Vice President, Chief Strategy Officer at Horizon Therapeutics. In that position, he was responsible for corporate strategy, M&A, business development, and portfolio management, and played a central role in Horizon's $28 billion acquisition by Amgen, Inc. in 2023.
His appointment is expected to leverage his experience in advising and building global biopharmaceutical companies to help Context advance its T cell engagers for solid tumors. This transition highlights the company's efforts to transform its Board to lead Context into its next phase of growth.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.